Capmatinib dihydrochloride hydrate (Standard)

Description

Capmatinib dihydrochloride hydrate Standard is the analytical standard of Capmatinib dihydrochloride hydrate . This product is intended for research and analytical applications. Capmatinib INC280; INCB28060 dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor IC50=0.13 nM . Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase.